Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of Ozempic and Wegovy injections has been “resolved.” Shares of Hims & Hers (HIMS), which markets compounded versions of the popular weight-loss drug, are down 15% in pre-market trading. Eli Lilly (LLY) also markets its own injectable weight-loss drug, Zepbound.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly (LLY) Stockpiles Weight Loss Pill Ahead of Regulatory Approval
- HIMS Stock Slips after Catching a Downgrade from Morgan Stanley
- Novo Nordisk call volume above normal and directionally bullish
- HIMS Stock Hits New ATH After Successful Super Bowl Ad
- CVS Health, Lyft report Q4 results: Morning Buzz